Neuropathic pain is defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”.
Characteristic symptoms include an increased evoked pain response to noxious (hyperalgesia) and innocuous (allodynia) stimuli, spontaneous pain, shooting electric shock like pain. Sensory deficits can also exist.
Available treatments are not adequate in many patients due to many factors including the complexity of the pain state, disease progression, intolerable side effects and low analgesic efficacy.
A number of peripheral, spinal and supraspinal mechanisms of hyperexcitability underlie neuropathic pain, these include changes in the activity and expression of voltage gated sodium, calcium and potassium channels, as well as TRPV1 channels and alterations in the activity of neuroimmue pathways.
NeP patients often experience depression, anxiety, sleep disturbances etc. alongside their pain. These comorbidites significantly reduce quality of life and as such are key treatment considerations.
Improved understanding of NeP mechanisms is encouraging targeting of treatment to the mechanisms that produce painful symptoms as opposed to the etiology of disease.
JensenMPChodroffMJDworkinRH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology.2007 Apr 10; 68 (15):1178–82.
3.
DworkinRHO'ConnorABAudetteJBaronRGourlayGKHaanpaaML. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc.2010 Mar; 85 (3 Suppl):S3–14.
4.
DevorM. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Experimental brain research Experimentelle Hirnforschung.2009 Jun; 196 (1):115–28.
5.
Dib-HajjSDCumminsTRBlackJAWaxmanSG. Sodium channels in normal and pathological pain. Annu Rev Neurosci.2010; 33:325–47.
6.
FischerTZWaxmanSG. Familial pain syndromes from mutations of the NaV1.7 sodium channel. Ann N Y Acad Sci.2010 Jan; 1184:196–207.
7.
NassarMALevatoAStirlingLCWoodJN. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Molecular pain.2005; 1:24.
8.
McGaraughtySChuKLScanioMJKortMEFaltynekCRJarvisMF. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl) furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. The Journal of pharmacology and experimental therapeutics.2008 Mar; 324 (3):1204–11.
9.
HoytSBLondonCGorinDWyvrattMJFisherMHAbbadieC. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. Bioorganic & medicinal chemistry letters.2007 Aug 15; 17 (16):4630–4.
10.
GhelardiniCDesaphyJFMuragliaMCorboFMatucciRDipalmaA. Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. Neuroscience.2010 Aug 25; 169 (2):863–73.
11.
CaoXHByunHSChenSRCaiYQPanHL. Reduction in voltage-gated K+ channel activity in primary sensory neurons in painful diabetic neuropathy: role of brain-derived neurotrophic factor. Journal of neurochemistry.2010 Sep 1; 114 (5):1460–75.
12.
CostiganMBelferIGriffinRSDaiFBarrettLBCoppolaG. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain.2010 Sep; 133 (9):2519–27.
13.
JiangYQSunQTuHYWanY. Characteristics of HCN channels and their participation in neuropathic pain. Neurochemical research.2008 Oct; 33 (10):1979–89.
14.
JonesVMMooreKAPetersonDM. Capsaicin 8% topical patch (qutenza)-a review of the evidence. J Pain Palliat Care Pharmacother.2011; 25 (1):32–41.
15.
BinderAMayDBaronRMaierCTolleTRTreedeRD. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One.2011; 6 (3):e17387.
16.
LatremoliereACostiganM. GCH1, BH4 and Pain. Curr Pharm Biotechnol.2011 Apr 5.
17.
FinnerupNBSindrupSHJensenTS. The evidence for pharmacological treatment of neuropathic pain. Pain.2010 Sep; 150 (3):573–81.
18.
DooleyDJTaylorCPDonevanSFeltnerD. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends in pharmacological sciences.2007 Feb; 28 (2):75–82.
19.
ManeufYPLuoZDLeeK. Alpha2Delta and the mechanism of action of gabapentin in the treatment of pain. Seminars in cell & developmental biology.2006 Oct; 17 (5):565–70.
20.
BauerCSNieto-RostroMRahmnaWTran-Van-MinhAFerronLDouglasL. The increased trafficking of the calcium channel subunit α2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the α2δ ligan pregabalin. J Neurosci.2009;in press.
21.
IwataHTakasusukiTYamaguchiSHoriY. NMDA receptor 2B subunit-mediated synaptic transmission in the superficial dorsal horn of peripheral nerve-injured neuropathic mice. Brain research.2007 Mar 2; 1135 (1):92–101.
22.
ImaiAHizueMToideK. Synergy between a NR2B receptor antagonist DHQ and 3-methyl-gabapentin in mice with neuropathic pain. European journal of pharmacology.2008 Jul 7; 588 (2–3):244–7.
23.
LiuXJGingrichJRVargas-CaballeroMDongYNSengarABeggsS. Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nature medicine.2008 Dec; 14 (12):1325–32.
24.
FischerTZWaxmanSG. Neuropathic pain in diabetes-evidence for a central mechanism. Nat Rev Neurol.2010 Aug; 6 (8):462–6.
25.
BannisterKBeeLADickensonAH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics.2009 Oct; 6 (4):703–12.
26.
TraceyIMantyhPW. The cerebral signature for pain perception and its modulation. Neuron.2007 Aug 2; 55 (3):377–91.
27.
SuzukiRRahmanWHuntSPDickensonAH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain research.2004; 1019 (1–2):68–76.
SuzukiRRahmanWRyghLJWebberMHuntSPDickensonAH. Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain.2005 Oct; 117 (3):292–303.
30.
BeeLADickensonAH. Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain.2008 Nov 15; 140 (1):209–23.
31.
OssipovMH. Growth Factors and Neuropathic Pain. Curr Pain Headache Rep.2011 Feb 16.
32.
SimpsonDMGazdaSBrownSWebsterLRLuSPTobiasJK. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. Journal of pain and symptom management.2010 Jun; 39 (6):1053–64.
33.
AttalNCruccuGBaronRHaanpaaMHanssonPJensenTS. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol.2010 Sep; 17 (9):1113–e88.
34.
HildebrandMESmithPLBladenCEduljeeCXieJYChenL. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain.2011 Apr; 152 (4):833–43.
35.
BeeLABannisterKRahmanWDickensonAH. Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain.2010 Jan; 152 (1):131–9.
36.
HartrickCTRozekRJ. Tapentadol in Pain Management: A mu-Opioid Receptor Agonist and Noradrenaline Reuptake Inhibitor. CNS Drugs.2011 May 1; 25 (5):359–70.
37.
GuanYWacnikPWYangFCarteretAFChungCYMeyerRA. Spinal cord stimulation-induced analgesia: electrical stimulation of dorsal column and dorsal roots attenuates dorsal horn neuronal excitability in neuropathic rats. Anesthesiology.2010 Dec; 113 (6):1392–405.
38.
WestMWuH. Pulsed radiofrequency ablation for residual and phantom limb pain: a case series. Pain Pract.2010 Sep-Oct; 10 (5):485–91.
39.
SongZMeyersonBALinderothB. Spinal 5-HT receptors that contribute to the pain-relieving effects of spinal cord stimulation in a rat model of neuropathy. Pain. 2011 Apr 22.
